Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake. In phase 2 and phase 3 trials, Cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile.
